Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Respiratory Inhaler Market -- Insights

Respiratory inhaler are used to inhale medicines that are important part of the treatment for chronic lung diseases. There are several products that deliver medicine directly to the airways such as metered-dose inhalers (MDIs), dry powder inhalers, nebulizers, and soft mist inhalers.

Statistics:

The global Respiratory Inhaler Market is estimated to account for US$ 32,921.8 Mn in terms of value and is expected to reach US$ 46,984.1 Mn by the end of 2027.

Global Respiratory Inhaler Market: Drivers

Increasing prevalence of asthma is expected to boost growth of the global Respiratory Inhaler Market over the forecast period. For instance, according to The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the number is expected to reach 100 million by 2025.

Moreover, high incidence of Chronic Obstructive Pulmonary Disease (COPD) is also expected to aid in growth of the market. For instance, according to a report by Global Initiative for Chronic Obstruction Disease’s 2018 report, COPD is expected to result in 4.5 million global deaths annually by 2030.

North America region held dominant position in the global Respiratory Inhaler Market in 2018, accounting for 40.4% share in terms of value, followed by Europe.

Respiratory Inhalers  | Coherent Market Insights

Global Respiratory Inhaler Market: Restraints 

Increasing cost of inhalers is a major factor hampering growth of the global Respiratory Inhaler Market. For instance, the average cost of one inhaler of Advair increased from US$ 316 Mn in 2013 to US$ 496 Mn in 2018 and that of Flovent increased from US$ 207 Mn in 2013 to US$ 292 Mn in 2018.

Moreover, increasing adoption of alternative therapies such as oral medication or subcutaneous injections that are freely available at various government-run hospitals, especially in emerging economies, and some other non-profit organizations is also expected to restrict growth of the market over the forecast period.

Global Respiratory Inhaler Market: Opportunities

Smart inhaler technology is a novel technology developed to help the patients in keeping a check on their doses and offers various other features. Smart inhalers have embedded electronic chip along with Bluetooth connectivity. One such company Adherium, Ltd.’s smart inhaler sensors are available for metered dose inhalers, dry powder inhalers, and nebulizers. These devices come with touchscreens and audio-visual medication reminders and additional advantages such as mobile application connectivity, cloud-based portals for researchers and clinicians, custom user interface options. Adherium, Ltd.’s Smartinhaler Live platform uses wireless technology to provide real-time data collection

Respiratory Inhalers  | Coherent Market Insights

Dry powder inhaler sub segment in product type segment in the global Respiratory Inhaler Market was valued at US$ 7,258.0 Mn in 2018 and is expected to reach US$ 10,111.6 Mn by 2027 at a CAGR of 3.6% during the forecast period.

Market Trends/Key Takeaways

The demand for nebulizers has significantly decreased as it involves a time consuming process and requires substantial effort in inhaling medicines. Moreover, nebulizers require regular maintenance. However, nebulizers can be useful for young children and some people with more severe or acute asthma. Nebulizers are also still used for the treatment of people who are unable to use an inhaler or other device due to weakness of hands or coordination problems or have excess mucus in the airways.

The market is also witnessing increasing adoption of propeller systems in inhaler devices, especially for the treatment of patients suffering from asthma or COPD. Propellers involve use of sensors, mobile apps, analytics and services to provide effective health care.

Global Respiratory Inhaler Market: Competitive Landscape

Major players operating in the global Respiratory Inhaler Market include, AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.

Global Respiratory Inhaler Market: Key Developments

Key players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in January 2020, Senzer Pharmaceuticals partnered with Drug Science, a leading independent scientific body on drugs in the U.K. running Project TWENTY21, under which Senzer Pharmaceuticals’ pharmaceutical respiratory device will be used in Project TWENTY21, a medical cannabis registry in Europe.

Key players in the market are focused on commercialization of their products to enhance their market share. For instance, in December 2019, Glenmark Pharmaceuticals Ltd. secured National Pharmaceutical Pricing Authority’s (India) nod for separate price for its digital dose inhaler or ‘Digihaler’.

An inhaler (puffer, spray or pump) is a medical device that is used for delivering medication into the body via lungs. It is used for releasing medication in the body to treat respiratory diseases such as bronchitis, asthma, allergic rhinitis, Chronic Obstructive Pulmonary Disorder (COPD), pneumonia, and sinusitis.  All these diseases can significantly restrain the physical activities of the individual. Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Respiratory Inhaler Market

Patients often struggle while using respiratory inhalers due to complex functioning, if not taught properly by trained healthcare professionals, which drives patient to opt for other route of administration. Improper use of inhalers reduces its effectiveness drastically, so, patients need to be monitored at regular intervals and inhalers need to be prescribed based on individual technical abilities. This factor is expected to restrain growth of the market up to certain extent.

Key features of the study:

  • This report provides in-depth analysis of the global Respiratory Inhaler Market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Respiratory Inhaler Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Respiratory Inhaler Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  •  Global Respiratory Inhaler Market, By Product Type:
    • Dry Powder Inhaler
    • Metered Dose Inhaler
    • Nebulizer
      • Ultrasonic Nebulizer
      • Compressed Air Nebulizer
      • Mesh Nebulizer
  • Global Respiratory Inhaler Market, By Technology:
    • Manually Operated Inhaler Devices
    • Digitally Operated Inhaler Devices
  • Global Respiratory Inhaler Market, By Disease Indication:
    • Asthma
    • COPD
    • Pulmonary Arterial Hypertension
    • Others
  • Global Respiratory Inhaler Market, By Geography:
    • North America
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
        • Manually Operated Inhaler Devices
        • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
        • Manually Operated Inhaler Devices
        • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
          • Manually Operated Inhaler Devices
          • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
        • Manually Operated Inhaler Devices
        • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
        • Manually Operated Inhaler Devices
        • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Dry Powder Inhaler
        • Metered Dose Inhaler
        • Nebulizer
          • Ultrasonic Nebulizer
          • Compressed Air Nebulizer
          • Mesh Nebulizer
      • By Technology:
        • Manually Operated Inhaler Devices
        • Digitally Operated Inhaler Devices
      • By Disease Indication
        • Asthma
        • COPD
        • Pulmonary Arterial Hypertension
        • Others
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • AstraZeneca plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Beximco Pharmaceuticals Ltd.
    • Boehringer Ingelheim GmbH
    • Cipla Ltd.
    • GlaxoSmithKline plc.
    • Koninklijke Philips N.V.
    • Merck & Co., Inc.
    • OMRON Healthcare Europe B.V.
    • PARI Medical Holding
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Technology
      • Market Snippet, By Disease Indication
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Respiratory Inhaler Market, By Product Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Dry Powder Inhaler
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Metered Dose Inhaler
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Nebulizer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Ultrasonic Nebulizer
    • Compressed Air Nebulizer
    • Mesh Nebulizer
  5. Global Respiratory Inhaler Market, By Technology, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Manually Operated Inhaler Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Digitally Operated Inhaler Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  6. Global Respiratory Inhaler Market, By Disease Indication, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Asthma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • COPD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Pulmonary Arterial Hypertension
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  7. Global Respiratory Inhaler Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Beximco Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cipla Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • OMRON Healthcare Europe B.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • PARI Medical Holding
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 25 figures on “Respiratory Inhaler Market – Global forecast to 2027.

Frequently Asked Questions

The global respiratory inhalers market is estimated to reach US$ 46,984.1 Million by the end of 2027.
Major players operating in the global respiratory inhalers market include AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
Increasing adoption of alternative therapies such as oral medication or subcutaneous injections that are freely available at various government-run hospitals, especially in emerging economies is one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing prevalence of asthma is one of the major factors that is expected to propel growth of the market over the forecast period.
The global respiratory inhalers market is estimated to account for US$ 32,921.8 Million in 2019, in terms of value.
Among regions, North America held dominant position in the global respiratory inhalers market in 2018, accounting for 40.4% share, in terms of value, followed by Europe.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner